ABSTRACT
Background Thromboses in unusual locations after the COVID-19 vaccine ChAdOx1-S have been reported. Better understanding of population-level thrombotic risks after COVID-19 vaccination is needed.
Methods We analysed linked electronic health records from adults living in England, from 8th December 2020 to 18th March 2021. We estimated incidence rates and hazard ratios (HRs) for major arterial, venous and thrombocytopenic outcomes 1-28 and >28 days after first vaccination dose for ChAdOx1-S and BNT162b2 vaccines. Analyses were performed separately for ages <70 and ≥70 years, and adjusted for age, sex, comorbidities, and social and demographic factors.
Results Of 46,162,942 adults, 21,193,814 (46%) had their first vaccination during follow-up. Adjusted HRs 1-28 days after ChAdOx1-S, compared with unvaccinated rates, at ages <70 and ≥70 respectively, were 0.97 (95% CI: 0.90-1.05) and 0.58 (0.53–0.63) for venous thromboses, and 0.90 (0.86-0.95) and 0.76 (0.73-0.79) for arterial thromboses. Corresponding HRs for BNT162b2 were 0.81 (0.74–0.88) and 0.57 (0.53–0.62) for venous thromboses, and 0.94 (0.90-0.99) and 0.72 (0.70-0.75) for arterial thromboses. HRs for thrombotic events were higher at younger ages for venous thromboses after ChAdOx1-S, and for arterial thromboses after both vaccines.
Rates of intracranial venous thrombosis (ICVT) and thrombocytopenia in adults aged <70 years were higher 1-28 days after ChAdOx1-S (adjusted HRs 2.27, 95% CI:1.33– 3.88 and 1.71, 1.35–2.16 respectively), but not after BNT162b2 (0.59, 0.24–1.45 and 1.00, 0.75–1.34) compared with unvaccinated. The corresponding absolute excess risks of ICVT 1-28 days after ChAdOx1-S were 0.9–3 per million, varying by age and sex.
Conclusions Increases in ICVT and thrombocytopenia after ChAdOx1-S vaccination in adults aged <70 years were small compared with its effect in reducing COVID-19 morbidity and mortality, although more precise estimates for adults <40 years are needed. For people aged ≥70 years, rates of arterial or venous thrombotic, events were generally lower after either vaccine.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://github.com/BHFDSC/CCU002_02
Funding Statement
FUNDING The British Heart Foundation Data Science Centre (grant No SP/19/3/34678 awarded to Health Data Research (HDR) UK) funded co-development (with NHS Digital) of the trusted research environment provision of linked datasets data access user software licences computational usage and data management and wrangling support. Support was also provided through the Data and Connectivity and Longitudinal Health and Wellbeing National Core Studies which were established through the UK Government Chief Scientific Adviser National Core Studies programme to coordinate COVID-19 priority research. Consortium partner organisations funded the time of contributing data analysts biostatisticians epidemiologists and clinicians.
WW is supported by the Chief Scientist Office (CAF/01/17). CS AW and WW are supported by Stroke Association (SA CV 20/100018). WW has given expert testimony to UK courts.
AMW is supported by the BHF-Turing Cardiovascular Data Science Award (BCDSA/100005) and by core funding from UK MRC (MR/L003120/1) BHF (RG/13/13/30194; RG/18/13/33946) and NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). AMW is part of the BigData@Heart Consortium funded by the Innovative Medicines Initiative-2 Joint Undertaking under grant agreement No 116074. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.
JAC JS and RD are supported by the Health Data Research (HDR) UK South West Better Care Partnership and the NIHR Bristol Biomedical Research Centre at University Hospitals Bristol, and Weston NHS Foundation Trust and the University of Bristol.
VMW is supported by the Medical Research Council Integrative Epidemiology Unit which receives its funding from the Medical Research Council and the University of Bristol (MC_UU_00011/4).
AA SD are supported by Health Data Research UK (grant number: HDR-9006) which receives its funding from the UK Medical Research Council Engineering and Physical Sciences Research Council Economic and Social Research Council Department of Health and Social Care (England) Chief Scientist Office of the Scottish Government Health and Social Care Directorates Health and Social Care Research and Development Division (Welsh Government) Public Health Agency (Northern Ireland) British Heart Foundation (BHF) and the Wellcome Trust; and Administrative Data Research UK, which is funded by the Economic and Social Research Council (grant number: ES/S007393/1).
This work uses data provided by patients and collected by the NHS as part of their care and support. We would also like to acknowledge all data providers who make anonymised data available for research.
Funders had no role in the study design, collection analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Newcastle & North Tyneside 2 Research Ethics Committee (20/NE/0161), the NHS Digital Data Access Request Service (DARS-NIC-381078-Y9C5K) and the British Heart Foundation Data Science Centre CVD-COVID-UK Approvals and Oversight Board.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Minor table changes
Data Availability
The de-identified data used in this study is available via the CVD-COVID-UK consortium coordinated by BHF Data Science Centre (https://www.hdruk.ac.uk/projects/cvd-covid-uk-project/) for accredited researchers working on approved projects in the NHS Digital trusted research environment. The study protocol, analytic and phenotyping code is available at: https://github.com/BHFDSC/CCU002_02
